SciELO - Scientific Electronic Library Online

 
vol.26 número3Insuficiência Respiratória Aguda: Dúvidas Existenciais do Internato em Medicina Interna índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Medicina Interna

versão impressa ISSN 0872-671X

Resumo

BRILHANTE, Dialina et al. Iron Metabolism, Biomarkers, Iron Overload and Chelation: Consensus in Myelodysplastic Syndromes. Medicina Interna [online]. 2019, vol.26, n.3, pp.223-231. ISSN 0872-671X.  https://doi.org/10.24950/rspmi/Revisao/225/18/3/2019.

Myelodysplastic syndromes (MDS) are a diverse group of myeloid neoplasias, characterized by cytopenias stemming from ineffective hematopoiesis and by an increased risk of progression to acute myeloid leukemia. They affect 5/100 000 people per year in Portugal, among which more than 60% will become transfusion-dependent during the course of the disease. Cytopenias may lead to significant morbidity and their correct management is the key to maintain these patients’ quality of life. This document gathers the result of the debate promoted by the Anemia Working Group Portugal with experts on the management of patients with lower risk MDS, addressing the medium- and long-term effects of recurrent transfusion and iron overload. For the diagnosis of MDS, the group recommends the use of World Health Organization classification published in 2016. The International Prognosis Scoring System score is still the reference score to define both the prognosis and the therapeutic strategy. Support therapy is a fundamental cornerstone in the management of MDS patients at any stage of the disease, and includes antibiotics, transfusion of erythrocytes and platelets, hematopoietic growth factors, antifibrinolytic agents and chelators. Chelation therapy should be considered in patients transfused with = 20 units of erythrocytes or with serum ferritin = 1000 ng/mL. Patients who are candidates to chelation should be submitted to periodic magnetic resonance imaging to the liver and the pancreas. Therapeutic options should take into account the individual characteristics of the disease for every patient and preserve the quality of live, in accordance with international guidelines.

Palavras-chave : Blood Transfusion; Chelation Therapy; Consensus; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes.

        · resumo em Português     · texto em Português     · Português ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons